Search research articles
Contact Us
Filters
Showing results (231-240 of 282) with videos related to
Page
of 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation
Wanling Xie, Meredith M Regan, Marc Buyse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 7, 2018
Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Megan Li, Flora Mulkey, Chen Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
Michael J Morris, Glenn Heller, David W Hillman, et al.
JCO Precision Oncology
|
April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
Howard I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Landon C Brown, Susan Halabi, Joseph D Schonhoft, et al.
JCO Precision Oncology
|
December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Nitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Timothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Page
of 29
Search research articles
Search
Showing results (231-240 of 282) with videos related to
Sort By:
Page
of 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation
Wanling Xie, Meredith M Regan, Marc Buyse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 7, 2018
Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Megan Li, Flora Mulkey, Chen Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
Michael J Morris, Glenn Heller, David W Hillman, et al.
JCO Precision Oncology
|
April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
Howard I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Landon C Brown, Susan Halabi, Joseph D Schonhoft, et al.
JCO Precision Oncology
|
December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Nitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Timothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Page
of 29